I Alpha-hydroxycholecalciferol: a Treatment of Renal Bone Disease

Overview

Journal Br Med J

Specialty General Medicine

Date 1975 Jan 4

PMID 1120218

Citations 6

Authors

G R Catto

M MacLeod

B PELC

E KODICEK

Affiliations

Soon will be listed here.

Abstract

Three patients with chronic renal failure on maintenance haemodialysis have been treated with 1 alpha-hydroxycholecalciferol (1 alpha-OHCC), a synthetic vitamin D analogue. A daily dose of 2 mug by mouth produced a significant increase in both calcium absorption from the gastrointestinal tract and calcium content of bone. Treatment with 1 alpha-OHCC appears to be effective in cases of metabolic bone disease associated with chronic renal failure.

Citing Articles

Studies on the mode of action of vitamin D XXXVII 1 alpha-hydroxyvitamin D3: a long-acting 1,25-dihydroxyvitamin D3 analog.

Walters M, Hunziker W, Bishop J, Norman A Calcif Tissue Int. 1983; 35(3):372-5.

PMID: 6307498 DOI: 10.1007/BF02405061.

Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.

Brickman A, Coburn J, FRIEDMAN G, Okamura W, Massry S, Norman A J Clin Invest. 1976; 57(6):1540-7.

PMID: 932193 PMC: 436813. DOI: 10.1172/JCI108424.

1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.

Postlethwaite R, Houston I Calcif Tissue Res. 1977; 22 Suppl:371-5.

PMID: 912549 DOI: 10.1007/BF02064103.

Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.

Kanis J, HENDERSON R, Heynen G, LEDINGHAM J, Russell R, Smith R Arch Dis Child. 1977; 52(6):473-81.

PMID: 879833 PMC: 1544715. DOI: 10.1136/adc.52.6.473.

Renal bone disease.

Catto G J R Coll Physicians Lond. 1976; 11(1):75-85.

PMID: 789876 PMC: 5368764.

References

Anderson J, OSBORN S, Tomlinson R, Newton D, RUNDO J, Salmon L . NEUTRON-ACTIVATION ANALYSIS IN MAN IN VIVO. A NEW TECHNIQUE IN MEDICAL INVESTIGATION. Lancet. 1964; 2(7371):1201-5. DOI: 10.1016/s0140-6736(64)91041-4. View

FLETCHER R, Jones J, MORGAN D . BONE DISEASE IN CHRONIC RENAL FAILURE. Q J Med. 1963; 32:321-9. View

Williams J, NICHOLSON G . A modified bone-biopsy drill for outpatient use. Lancet. 1963; 1(7296):1408. DOI: 10.1016/s0140-6736(63)92059-2. View

DENT C, Harper C, PHILPOT G . The treatment of renal-glomerular osteodystrophy. Q J Med. 1961; 30:1-31. View

STANBURY S . Azotaemic renal osteodystrophy. Br Med Bull. 1957; 13(1):57-60. DOI: 10.1093/oxfordjournals.bmb.a069572. View

DeLuca H . The kidney as an endocrine organ for the production of 1,25-dihydroxyvitamin D 3 , a calcium-mobilizing hormone. N Engl J Med. 1973; 289(7):359-65. DOI: 10.1056/NEJM197308162890710. View

Davies J, ANDREWS G, Miller R, Owen H . Comparison of the stannous chloride and vanadate methods for estimation of serum inorganic phosphorus by use of the "SMA 12-60". Clin Chem. 1973; 19(4):411-4. View

Catto G, McIntosh J, MacLeod M . Partial body neutron activation analysis in vivo: a new approach to the investigation of metabolic bone disease. Phys Med Biol. 1973; 18(4):508-17. DOI: 10.1088/0031-9155/18/4/003. View

Tripp E, MacKay E . Silver staining of bone prior to decalcification for quantitative determination of osteoid in sections. Stain Technol. 1972; 47(3):129-36. DOI: 10.3109/10520297209116467. View

10.

Cohn S, CINQUE T, Dombrowski C, LETTERI J . Determination of body composition by neutron activation analysis in patient with renal failure. J Lab Clin Med. 1972; 79(6):978-94. View

11.

HENDERSON R, Russell R, LEDINGHAM J, Smith R, Oliver D, WALTON R . Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet. 1974; 1(7854):379-84. DOI: 10.1016/s0140-6736(74)93149-3. View

12.

Coburn J, Hartenbower D, Massry S . Intestinal absorption of calcium and the effect of renal insufficiency. Kidney Int. 1973; 4(2):96-104. DOI: 10.1038/ki.1973.88. View

13.

CHALMERS T, Hunter J, Davie M, Szaz K, PELC B, KODICEK E . 1-Alpha-hydroxycholecalciferol as a substitute for the kidney hormone 1,25-dihydroxycholecalciferol in chronic renal failure. Lancet. 1973; 2(7831):696-9. DOI: 10.1016/s0140-6736(73)92536-1. View

14.

Mawer E, Taylor C, Backhouse J, LUMB G, STANBURY S . Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet. 1973; 1(7804):626-8. DOI: 10.1016/s0140-6736(73)92197-1. View

15.

Peacock M, Gallagher J, Nordin B . Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man. Lancet. 1974; 1(7854):385-89. DOI: 10.1016/s0140-6736(74)93150-x. View

16.

Brickman A, Norman A . Treatment of renal osteodystrophy with calciferol (vitamin D) and related steroids. Kidney Int. 1973; 4(2):161-7. DOI: 10.1038/ki.1973.95. View

17.

Boyle I, MIRAVET L, Gray R, Holick M, DeLuca H . The response of intestinal calcium transport to 25-hydroxy and 1,25-dihydroxy vitamin D in nephrectomized rats. Endocrinology. 1972; 90(3):605-8. DOI: 10.1210/endo-90-3-605. View

18.

Brickman A, Coburn J, Norman A . Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3, in uremic man. N Engl J Med. 1972; 287(18):891-5. DOI: 10.1056/NEJM197211022871801. View

19.

Holick M, Semmler E, Schnoes H, DeLuca H . 1 -Hydroxy derivative of vitamin D 3 : a highly potent analog of 1 ,25-dihydroxyvitamin D 3 . Science. 1973; 180(4082):190-1. DOI: 10.1126/science.180.4082.190. View

20.

Fraser D, KODICEK E . Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature. 1970; 228(5273):764-6. DOI: 10.1038/228764a0. View